We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Auctioning the crown jewels

18 February 2004 By Robert Cyran

If Aventis could secure a premium price for, say, its cardiovascular drugs, that would make Sanofi sweat. It would either have to increase its own hostile bid substantially or retreat with its tail between its legs.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)